Predicta Med, a provider of an AI-guided predictive clinical decision support platform that enables early detection and effective treatment recommendation for a range of chronic, autoimmune and immune-related diseases, received a strategic investment from CerraCap Ventures, a California headquartered venture capital firm.
According to the Centers for Disease Control, chronic disease is the leading cause of death and disability in the United States, accounting for 70% of all deaths.
The annual global spending on the diagnosis and treatment of chronic and autoimmune diseases exceeds $100 billion worldwide.
The new strategic funding will allow Predicta Med to expand its clinical decision tools, which help doctors treat millions of people with autoimmune and immune-related diseases. According to the company, its AI-based digital health and predictive analytics platform enables early detection and effective treatment selection for autoimmune and immune-related diseases. The platform allows clinicians to provide earlier recognition and identification and offer clinically validated work-up suggestions to reduce disease progression by combining expert medical knowledge with cutting-edge learning techniques.
Commenting on the investment, Abhi Mukherjee, Operating Partner, CerraCap Ventures, said, “Predicta Med has a clearly defined mission to improve the health of millions and has built a commendable early-mover advantage in creating a decision support platform to help early detection and intervention of chronic diseases that afflict more than 50 million Americans annually.”
Clinical intelligence software startups
According to our funding database, clinical decision support software startups have raised nearly $15 billion in funding to date. More recently, Perception Vision Medical Technologies (PVmed), a provider of AI-guided solutions that help doctors plan and treat cancers precisely, raised $14 million in Series A funding from Cherami Investment Group, Philips, JHF Investment, COCOCAPITAL Corporation, and Strategy Capital. In another deal, Kiyatec, a precision cancer treatment platform, raised $18 million in Series C funding led by Bruker, with participation from Seae Ventures, VentureSouth, and LabCorp.
